| Dr Daniel Enrique Ortiz, MD | |
|
1600 Sw Archer Rd, Gainesville, FL 32610-1804 | |
| (352) 294-8278 | |
| (352) 265-0379 |
| Full Name | Dr Daniel Enrique Ortiz |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 10 Years |
| Location | 1600 Sw Archer Rd, Gainesville, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871912477 | NPI | - | NPPES |
| 104234400 | Medicaid | FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | A140697 (California) | Secondary |
| 207R00000X | Internal Medicine | ME141794 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uf Health Shands Hospital | Gainesville, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Clinical Practice Association | 0345146254 | 1636 |
News Archive
Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
A month of daily transcranial magnetic stimulation targeting the supplemental motor area results in lasting improvements in symptoms of Tourette syndrome, show study findings.
Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.
Manhattan Cross Cultural Group is now offering a special introduction to the Quality Interactions® Patient Decision Support Tool for small healthcare organizations at http://www.qualityinteractions.org/index.new.html. This one-of-a-kind online resource allows healthcare organizations to access valuable information related to cross-cultural care to care for diverse patient populations at time of service.
› Verified 8 days ago
| Entity Name | Florida Clinical Practice Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063463768 PECOS PAC ID: 0345146254 Enrollment ID: O20031211000099 |
News Archive
Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
A month of daily transcranial magnetic stimulation targeting the supplemental motor area results in lasting improvements in symptoms of Tourette syndrome, show study findings.
Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.
Manhattan Cross Cultural Group is now offering a special introduction to the Quality Interactions® Patient Decision Support Tool for small healthcare organizations at http://www.qualityinteractions.org/index.new.html. This one-of-a-kind online resource allows healthcare organizations to access valuable information related to cross-cultural care to care for diverse patient populations at time of service.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Enrique Ortiz, MD Po Box 100238, Gainesville, FL 32610-0238 Ph: (352) 294-8278 | Dr Daniel Enrique Ortiz, MD 1600 Sw Archer Rd, Gainesville, FL 32610-1804 Ph: (352) 294-8278 |
News Archive
Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.
A month of daily transcranial magnetic stimulation targeting the supplemental motor area results in lasting improvements in symptoms of Tourette syndrome, show study findings.
Onyx Pharmaceuticals, Inc. today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor.
Manhattan Cross Cultural Group is now offering a special introduction to the Quality Interactions® Patient Decision Support Tool for small healthcare organizations at http://www.qualityinteractions.org/index.new.html. This one-of-a-kind online resource allows healthcare organizations to access valuable information related to cross-cultural care to care for diverse patient populations at time of service.
› Verified 8 days ago
Dr. Sheetal Patel, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1601 Sw Archer Rd, Gainesville, FL 32608 Phone: 800-324-8387 | |
Dr. Talal Seoud, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-273-9400 Fax: 352-627-4268 | |
Eric I Rosenberg, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-265-0651 Fax: 352-265-0153 | |
Dr. Eric Padron, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-265-0239 Fax: 352-338-9879 | |
Osman S Farooq, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1600 Sw Archer Rd, Gainesville, FL 32610 Phone: 352-559-5051 | |
Ilie Toma Barb, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4645 Nw 8th Ave, Gainesville, FL 32605 Phone: 352-264-2500 Fax: 352-416-0135 | |
Fernando Ortiz, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 4645 Nw 8th Ave, Gainesville, FL 32605 Phone: 352-375-1212 Fax: 352-371-4650 |